[1] Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev, 2013, 39(1):18-26.
[2]Paes FM, Ernani V, Hosein P, et al. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J Support Oncol, 2011, 9(6):197-205.
[3]Ebrahimi M, Assadi M, Rezaei MM. New bone pain palliation radiopharmaceuticals in Iran. Iran J Nucl Med, 2012, 20:135.
[4]Touchefeu Y, Franken P, Harrington KJ. Radiovirotherapy: principles and prospects in oncology. Curr Pharm Des, 2012, 18(22):3313-3320.
[5]Ogawa K, Washiyama K. Bone target radiotracers for palliative therapy of bone metastases. Curr Med Chem, 2012, 19(20):3290-3300.
[6]Turner JH. Outpatient therapeutic nuclear oncology. Ann Nucl Med, 2012, 26(4):289297.
[7]Pillai MR, Dash A, Knapp FF. Rhenium-188: availability from the (188)W/(188)Re generator and status of current applications. Curr Radiopharm, 2012, 5(3):228-243.
[8]Kalantari BA, Davarpanah MR, Ghannadi Maragheh M, et al. Synthesis and quality control of 188Re-HEDP and its biodisturbution studies in rats. Iran J Nucl Med, 2012, 20:133.
[9]Das T, Pillai MR. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol, 2013, 40(1):23-32.
[10]程爱萍, 陈绍亮, 陈曙光, 等. 显像法分析188Re-HEDP在肿瘤骨转移患者体内的分布. 实用肿瘤杂志, 2009, 24(3):254-259.
[11]Liepe K, Geidel HH, Bergmann R, et al. Autoradiographic studies of rhenium-188hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Nucl Med Commun, 2009, 30(9):693-699.
[12]Cheng A, Chen S, Zhang Y, et al. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cancer Biother Radiopharm, 2011, 26(2):237-244.
[13]Chiacchio S, Mazzarri S, Lorenzoni A, et al. Radionuclide therapy and integrated protocols for bone metastases. Q J Nucl Med Mol Imaging, 2011, 55(4):431-447.
[14]Roqué I, Figuls M, Martinez-Zapata MJ, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev, 2011, 6(7):CD003347.
[15]Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun, 2007, 28(8):623-630.
[16]Biersack HJ, Palmedo H, Andris A, et al. Palliation and survival after repeated (188)ReHEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med, 2011, 52(11):1721-1726.
[17]Biersack HJ, Palmedo H, Andris A, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer:a retrospective analysisReply. J Nucl Med, 2012, 53(8):1332.
[18]Lam MG, Bosma TB, van Rijk PP, et al. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase Ⅰ safety and toxicity study. Eur J Nucl Med Mol Imaging, 2009, 36(9):1425-1433.
[19]Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases. Methods, 2011, 55(3):258-270. |